Weber, S.; Meisgen, T. J.; Diekmann, J.; Wittig, A.; Rustemeier, K.
The water soluble fraction of the gas/vapor phase (GVP) of 2R4F cigarette mainstream smoke has been shown to be mutagenic in salmonella typhimurium strain TA100 without S9 metabolic activation in the microsuspension version of the salmonella reverse mutation assay. To estimate the contribution of single smoke constituents to the mutagenic activity of GVP from the reference cigarette 2R4F, GVP was screened for smoke constituents by a targeted GC/MS screening method and an HPLC method (formaldehyde only). 65 single smoke constituents, from 13 chemical classes were identified, with the aldehydes having the highest yields. The ten constituents with the highest yields, i.e., acetaldehyde, acetone, 2,3-butanedione, 2-butanone, acetonitrile, acrolein, propionaldehyde, methyl vinyl ketone, crotonaldehyde, and toluene, as well as five other constituents which are reported to be mutagenic, i.e., methacrolein, formaldehyde, benzene, pyridine, and 2-furaldehyde, were assayed as pure substances for their mutagenic activity. Results showed that the mutagenic activity of GVP from the 2R4F could be attributed mainly to six smoke constituents: acrolein, crotonaldehyde, formaldehyde, methyl vinyl ketone, methacrolein, and 2,3-butanedione. Of these six constituents, acrolein, crotonaldehyde, and formaldehyde account for approximately 60% of the mutagenicity.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.